Trials / Completed
CompletedNCT00717925
Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
A Phase 1 Study Of CMC-544 Administered As A Single Agent In Subjects With B-Cell Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inotuzumab Ozogamicin (CMC-544) | Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2008-07-18
- Last updated
- 2015-12-09
Source: ClinicalTrials.gov record NCT00717925. Inclusion in this directory is not an endorsement.